|
1) Budoff MJ, Cohen MC, Garcia MJ. ACCF/AHA clinical competence statement on cardiac imaging with computed tomography and magnetic resonance: A report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training. J Am Coll Cardiol. 2005; 46: 383-402
|
|
|
|
2) Schwitter J, Wacker CM, van Rossum AC. MR-IMPACT: comparison of perfusion-cardiac magnetic resonance with single-photon emission computed tomography for the detection of coronary artery disease in a multicentre, multivendor, randomized trial. Eur Heart J. 2008; 29: 480-9
|
|
|
|
|
|
3) Wagner A, Mahrholdt H, Holly TA. et al. Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: an imaging study. Lancet. 2003; 36: 374-9
|
|
|
|
|
|
4) Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000; 343: 1445-53
|
|
|
|
|
|
5) Hendel RC, Patel MR, Kramer CM, et al. ACCF/ACR/SCCT/SCMR/ASNC /NASCI/SCAI/SIR 2006 appropriateness criteria for cardiac computed tomography and cardiac magnetic resonance imaging: a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American College of Radiology, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, American Society of Nuclear Cardiology, North American Society for Cardiac Imaging, Society for Cardiovascular Angiography and Interventions, and Society of Interventional Radiology. J Am Coll Cardiol. 2006; 48: 1475-97
|
|
|
|
|
|
6) Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006; 113: 1807
|
|
|
|
|
|
7) Kim RJ, Fieno DS, Parrish TB, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation. 1999; 100: 1992-2002
|
|
|
|
|
|
8) McCrohon JA, Moon JCC, Prasad SK, et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation. 2003; 108: 54-9
|
|
|
|
|
|
9) Assomull RG, Prasad SK, Lyne J. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol. 2006; 48: 1977-85
|
|
|
|
|
|
10) Pons-Llado G, Carreras F, Borras X, et al. Comparison of morphologic assessment of hypertrophic cardiomyopathy by magnetic resonance versus echocardiographic imaging. Am J Cardiol. 1997; 79: 1651
|
|
|
|
|
|
11) Rickers C, Wilke NM, Jerosch-Herold M, et al. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation. 2005; 112: 855-61
|
|
|
|
|
|
12) Choudhury L, Mahrholdt H, Wagner A, et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002; 40: 2156-64
|
|
|
|
|
|
13) Moon JCC, Mckenna WJ, McCronhon JA, et al. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol. 2003. 41: 1561-76
|
|
|
|
|
|
14) Teraoka K, Hirano M, Ookubo Y, et al. Delayed contrast enhancement of MRI in hypertrophic cardiomyopathy. Magnetic Resonance Imaging. 2003; 22: 155-61
|
|
|
|
|
|
15) Teraoka K, Hirano M, Ogawa T, et al. Hypertrophic Cardiomyopathy with mid-ventricular obstruction complicated by apical aneurysm appearing as delayed contrast hyperenhancement on magnetic resonance imaging: two case reports. J Cardiol. 2003; 42: 87-94
|
|
|
|
|
16) Moon JCC, Reed E, Sheppard MN, et al. The histological basisi of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004; 43: 2260-4
|
|
|
|
|
|
17) Maceira AM, Joshi J, Parad SK, et al. Cardiovascular Magnetic Resonance in Cardiac Amylodosis. Circulation. 2005; 111: 186-93
|
|
|
|
|
|
18) Tandri H, Saranathan M, Rodriguez ER, et al. Noninvasive Detection of myocardial fibrosis in arrhythmogenic right ventricular cardiomyopathy using delayed-enhancenced magnetic resonance imaging. J Am Coll Cardiol. 2005: 45: 98-103
|
|
|
|
|
|
19) Petersen SE, et al. Left ventricular non-compaction: insights from cardiovascular magnetic resonance imaging. J Am Coll Cardiol. 2005; 46: 101-5
|
|
|
|
|
|
20) Teraoka K, Kiuchi S, Takada N, et al. Images in cardiovascular medicine. No delayed enhancement on contrast magnetic resonance imaging with Takotsubo cardiomyopathy. Circulation. 2005; 111: e261-2
|
|
|
|
|
|
21) Kiuch S, Teraoka K, et al. Usefulness of late gadolinium enhancement combined with MRI and 67-Ga scintigraphy in the diagnosis of cardiac sarcoidosis and disease activity evaluation. Int J Cardiovasc Imaging. 2007; 23: 237-41
|
|
|
|
|
|
22) Semedema JP, Snoep G, Kroonenburgh MPG, et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardia c sarcoidosis. J Am Coll Cardiol. 2005; 45: 1683-90
|
|
|
|
|